

- I to IV. Claims 1-2, in so far as they are drawn to any one of the four biopolymer marker sequences recited therein, classified in class 530, subclass 300. For example, Invention I consists of claims 1-2 only in so far as they encompass a biopolymer marker of SEQ ID NO: 1. Invention IV consists of claims 1-2 only in so far as they encompass a biopolymer marker of SEQ ID NO: 4.
- V to VIII. Claims 3-9, in so far as they are drawn to a method for evidencing a disease by evidencing any one of four biopolymer marker sequences, classified in class 424, subclass 86, for example.
- IX to XII. Claims 10-28, in so far as it is drawn to a diagnostic kit comprising a material capable of binding to any one of four biopolymer markers, classified in class 424, subclass 130.1, for example.
- XIII to XIV. Claims 29-32, in so far as they are drawn to an antibody that binds to any one of four biopolymer markers, classified in class 530, subclass 397.1, for example.
- XVII to XX. Claims 33-37, in so far as they are drawn to a process for identifying therapeutic avenues by using any one of four biopolymer markers, classified in class 435, subclass 7.1, for example.
- XXI to XIV. Claim 38, in so far as they are drawn to a process for regulating a disease state by controlling the presence or absence of any one of four biopolymer markers, classified in class undetermined, subclass undetermined, for example.

Applicants hereby elect with traverse Group I (claims 1 and 2 as drawn to SEQ ID NO:1) for prosecution on the merits.

It is noted that the Examiner has also required an election of species under 35 U.S.C. 121